TRACON Pharmaceuticals

TRACON Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration and fibrotic diseases. Its lead product candidate, TRC105, is an anti-endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with inhibitors of the VEGF pathway. The Company's other product candidates are TRC205, an anti-endoglin antibody that is in preclinical development for the treatment of fibrotic diseases, and TRC102, a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma. 
Company Growth (employees)
Type
Public
HQ
San Diego, US
Founded
2006
Size (employees)
26 (est)
TRACON Pharmaceuticals was founded in 2006 and is headquartered in San Diego, US

Key People at TRACON Pharmaceuticals

Charles P. Theuer

Charles P. Theuer

President and CEO

TRACON Pharmaceuticals Office Locations

TRACON Pharmaceuticals has an office in San Diego
San Diego, US (HQ)
4350 La Jolla Village Dr

TRACON Pharmaceuticals Data and Metrics

TRACON Pharmaceuticals Financial Metrics

USD

Net income (Q1, 2017)

(7.1 m)

EBIT (Q1, 2017)

(6.9 m)

Market capitalization (18-Aug-2017)

36.5 m

Cash (31-Mar-2017)

32.2 m
TRACON Pharmaceuticals's current market capitalization is $36.5 m.
USDFY, 2015FY, 2016

R&D expense

25.7 m21.6 m

General and administrative expense

5.7 m7.9 m

Operating expense total

31.4 m29.4 m

EBIT

(23.5 m)(26 m)

Interest expense

923 k1.1 m

Net Income

(24.4 m)(27 m)
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

R&D expense

5.4 m5.9 m5.5 m6.8 m4.5 m5.6 m

General and administrative expense

1.5 m1.5 m2 m2 m1.9 m2 m

Operating expense total

6.9 m7.4 m7.5 m8.8 m6.4 m7.5 m

EBIT

2.7 m(6.2 m)(6.3 m)(8 m)(5.6 m)(6.9 m)

Interest expense

224 k221 k293 k291 k287 k225 k

Net Income

(2.9 m)(6.4 m)(6.5 m)(8.3 m)(5.9 m)(7.1 m)
USDFY, 2015FY, 2016

Cash

41.4 m35.7 m

Accounts Receivable

9.4 m

Inventories

8 m

Current Assets

53.3 m45.6 m

PP&E

173 k82 k

Total Assets

53.5 m45.7 m

Accounts Payable

8.3 m6.2 m

Current Liabilities

14.2 m10.2 m

Additional Paid-in Capital

89.6 m113.9 m

Retained Earnings

(58.6 m)(85.6 m)

Total Equity

31 m28.3 m

Financial Leverage

1.7 x1.6 x
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

47.2 m43.3 m34 m29.6 m32.2 m

Current Assets

59.9 m46.8 m37.7 m36.5 m37.8 m

PP&E

141 k152 k128 k106 k75 k

Total Assets

60 m47 m37.9 m36.6 m37.9 m

Accounts Payable

7 m8.6 m6.6 m6.7 m5.7 m

Current Liabilities

11.6 m14.2 m13.2 m13.2 m7.8 m

Additional Paid-in Capital

88.6 m90.4 m91.5 m97.1 m115.7 m

Retained Earnings

(47.5 m)(65.1 m)(73.4 m)(79.3 m)(92.7 m)

Total Equity

41.1 m25.3 m18.1 m17.8 m23 m

Financial Leverage

1.5 x1.9 x2.1 x2.1 x1.6 x
USDFY, 2015FY, 2016

Net Income

(24.4 m)(27 m)

Depreciation and Amortization

94 k

Accounts Payable

(2.2 m)

Cash From Operating Activities

(27.2 m)

Purchases of PP&E

(3 k)

Cash From Investing Activities

2.1 m

Long-term Borrowings

(2 m)

Cash From Financing Activities

19.4 m

Interest Paid

622 k
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(2.9 m)(6.4 m)(6.5 m)(8.3 m)(5.9 m)(7.1 m)

Accounts Payable

3.5 m6.1 m7 m8.6 m6.6 m6.7 m5.7 m
Y, 2017

Financial Leverage

1.6 x

TRACON Pharmaceuticals Market Value History

Traffic Overview of TRACON Pharmaceuticals

TRACON Pharmaceuticals Company Life and Culture

You may also be interested in